Rejected petition Grant brain tumour patients access to Vorasidenib

Low grade brain tumours have few effective medicines. A recent trial shows Vorasidenib is effective and prolongs life. I ask the UK government to make Vorasidenib available to clinically suitable brain tumour patients in the UK under the Early Access to Medicines Scheme

More details

Trials have taken place in the US and the UK on Low Grade Glioma brain tumour patients. Low Grade Gliomas affect mainly young people. Results of the trials proved very promising. The drug will soon receive FDA approval in the US.

The trials were stopped abruptly in March 2023. There was enough evidence that Vorasidenib significantly reduced the risk of tumour progression or death. The supplier of Vorasidenib has suggested it may make the drug available on a patient-by-patient basis.

This petition was rejected

Why was this petition rejected?

It’s about something that the UK Government or Parliament is not directly responsible for.

We can only accept petitions about things the Government or Parliament are directly responsible for.

Authorising medication for use in the UK is the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA), not the UK Government of Parliament. The decision to apply for the Early Access to Medicines Scheme is for pharmaceutical companies and a decision on the outcome of an application is for the MHRA. You can find out more about the process here: https://www.gov.uk/guidance/apply-for-the-early-access-to-medicines-scheme-eams

We only reject petitions that don’t meet the petition standards.

Date submitted 29 August 2023
Get petition data (json format)

About petition data

The data shows the number of people who have signed the petition by country as well as in the constituency of each Member of Parliament. This data is available for all petitions on the site. It is not a list of people who have signed the petition. The only name that is shared on the site is that of the petition creator.